COVID 19 and its management

2021 ◽  
pp. 117-121
Author(s):  
Subhashis Debnath ◽  
Runa Chakravorty ◽  
Donita Devi
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
The Elderly ◽  
Public Health Emergency ◽  
Novel Coronavirus

In December 2019, severe acute respiratory syndrome-coronavirus-2, a novel coronavirus, initiated an outbreak of pneumonia from Wuhan in China, which rapidly spread worldwide. The outbreak was declared as “a public health emergency of international concern” by the WHO on January 30, 2020, and as a pandemic on March 11, 2020. The disease is transmitted by inhalation or contact with infected droplets and the incubation period ranges from 2 to 14 d. The symptoms are usually fever, cough, sore throat, breathlessness, fatigue, malaise among others. The disease is mild in most people; in some (usually the elderly and those with comorbidities), it may progress to pneumonia, acute respiratory distress syndrome (ARDS) and multi organ dysfunction. Many people are asymptomatic. The virus spreads faster than its two ancestors the SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), but has lower fatality.

scholarly journals Pneumomediastinum in COVID-19 Patients

2020 ◽  
pp. 7-9
Author(s):  
Sebastián Campbell-Quintero ◽  
Santiago Campbell-Quintero ◽  
Santiago Campbell-Silva
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Infectious Diseases ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Emerging Infectious Diseases ◽  
Major Threat ◽  
Novel Coronavirus

Emerging infectious diseases, such as severe acute respiratory syndrome (SARS), present a major threat to public health. In December 2019, a novel coronavirus referred to as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the causative agent of a respiratory syndrome named coronavirus disease 2019 (COVID-19). Since then, the pandemic has escalated. The spectrum of COVID-19 presentations ranges from mild self-limited flulike illness to severe viral pneumonia leading to acute respiratory distress syndrome that can be potentially fatal.

scholarly journals Gangguan Koagulasi Pada Pasien Covid-19

2021 ◽  
Vol 2 (2) ◽  
pp. 63-72
Author(s):  
TUTIK HARJIANTI
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Venous Thromboembolism ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Middle East Respiratory Syndrome ◽  
D Dimer

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) merupakan famili dari coronavirus, sudah dua kali menyababkan kejadian luar biasa  yaitu di tahun 2003 dengan SARS (Severe Acute Respiratory Syndrome) dan tahun 2012 dengan penyakit  MERS (Middle East Respiratory Syndrome). Pada tahun 2019 SARS-CoV-2 telah menyebabkan pandemi global kembali. Pertama kali diidentifikasi di Wuhan, Cina. Dan telah menyebar ke seluruh negara dengan jumlah kasus yang terus meningkat secara eksponensial diseluruh dunia. Pada Maret 2020 oleh WHO dinyatakan pandemic. (Covid-19), menyebabkan pneumonia dan beberapa kondisi dapat terjadi Acute Respiratory Distress Syndrome (ARDS) serta beberapa manifestasi ekstra paru, seperti kardiovaskular, saluran cerna, ginjal ,hematologi, sekuele akibat trombosis dan progresifitas disfungsi organ.1 Prognosis pada pasien Covid-19 salah satu tanda ,gejalanya adalah terjadinya gangguan koagulasi, yang ditandai dengan meningkatnya nilai D dimer sebagai tanda awal kondisi thrombosis dan  salah satunya dapat bermanifestasi sebagai Venous Thromboembolism (VTE). Pada pasien dengan Covid-19, kondisi koagulopati adalah salah satu kunci dan tanda persisten yang terkait dengan outcome yang buruk.1,2   

scholarly journals Intubation and mechanical ventilation of patients with COVID-19: what should we tell them?

2020 ◽  
Vol 90 (1) ◽  
Author(s):  
Nicholas Zareifopoulos ◽  
Maria Lagadinou ◽  
Anastasia Karela ◽  
Gerasimos Karantzogiannis ◽  
Dimitrios Velissaris
Keyword(s):  
Mechanical Ventilation ◽  
Acute Respiratory Distress Syndrome ◽  
Informed Consent ◽  
Middle East ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Middle East Respiratory Syndrome

Severe COVID-19 illness is characterised by the development of Acute Respiratory Distress Syndrome (ARDS), for which the mainstay of treatment is represented by mechanical ventilation. Mortality associated with ARDS due to other causes is in the range of 40-60%, but currently available data are not yet sufficient to draw safe conclusions on the prognosis of COVID-19 patients who require mechanical ventilation. Based on data from cohorts of the related coronavirus-associated illnesses, that is to say Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), prognosis would seem to be worse than ARDS due to other causes such as trauma and other infections. Discussion of prognosis is central to obtaining informed consent for intubation, but in the absence of definitive data it is not clear exactly what this discussion should entail.

scholarly journals Severe Acute Respiratory Syndrome Coronavirus-2 Induces Cytokine Storm and Inflammation During Coronavirus Disease 19: Perspectives and Possible Therapeutic Approaches

2020 ◽  
Vol 11 ◽  
Author(s):  
Federica Mannino ◽  
Alessandra Bitto ◽  
Natasha Irrera
Keyword(s):  
Public Health ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Distress Syndrome ◽  
Severe Pneumonia ◽  
Public Health Emergency ◽  
Cytokine Storm ◽  
Global Public Health ◽  
Therapeutic Approaches

The new coronavirus outbreak was first identified in Wuhan, China, in December 2019, and has turned out to be a global health emergency, affecting millions of people worldwide. Coronavirus disease 19 (COVID-19), caused by the SARS-CoV-2 virus, can manifest with flu-like symptoms and can be complicated by severe pneumonia with acute respiratory distress syndrome (ARDS); however a large percentage of infected individuals do not have symptoms but contribute to the spread of the disease. Severe acute respiratory syndrome coronavirus-2 infection has become a global public health emergency since no available treatment seems effective and it is hard to manage the several complications caused by an intense release of cytokines. This paper reviews the current options on drugs used to reduce the deadly effects of the cytokine storm.

Cytokine storm syndrome in SARS-CoV-2: a review

2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Braira Wahid ◽  
Noshaba Rani ◽  
Muhammad Idrees
Keyword(s):  
Acute Respiratory Distress Syndrome ◽  
Respiratory Failure ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Distress Syndrome ◽  
Cytokine Storm ◽  
Global Level ◽  
Management Option ◽  
Human Contact

Abstract After wreaking havoc on a global level with a total of 5,488,825 confirmed cases and 349,095 deaths as of May 2020, severe acute respiratory syndrome coronavirus 2 is truly living up to the expectations of a 21st-century pandemic. Since the major cause of mortality is a respiratory failure from acute respiratory distress syndrome, the only present-day management option is supportive as the transmission relies solely on human-to-human contact. Patients suffering from coronavirus disease 2019 (COVID-19) should be tested for hyper inflammation to screen those for whom immunosuppression can increases chances of survival. As more and more clinical data surfaces, it suggests patients with mild or severe cytokine storms are at greater risk of failing fatally and hence these cytokine storms should be targets for treatment in salvaging COVID-19 patients.

scholarly journals Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection

2009 ◽  
Vol 83 (14) ◽  
pp. 7062-7074 ◽  
Author(s):  
Barry Rockx ◽  
Tracey Baas ◽  
Gregory A. Zornetzer ◽  
Bart Haagmans ◽  
Timothy Sheahan ◽  
...  
Keyword(s):  
Immune Response ◽  
Acute Respiratory Distress Syndrome ◽  
Severe Acute Respiratory Syndrome ◽  
Respiratory Distress Syndrome ◽  
Respiratory Distress ◽  
Host Response ◽  
Molecular Mechanisms ◽  
Distress Syndrome ◽  
Aged Mice ◽  
Young Mice

ABSTRACT Several respiratory viruses, including influenza virus and severe acute respiratory syndrome coronavirus (SARS-CoV), produce more severe disease in the elderly, yet the molecular mechanisms governing age-related susceptibility remain poorly studied. Advanced age was significantly associated with increased SARS-related deaths, primarily due to the onset of early- and late-stage acute respiratory distress syndrome (ARDS) and pulmonary fibrosis. Infection of aged, but not young, mice with recombinant viruses bearing spike glycoproteins derived from early human or palm civet isolates resulted in death accompanied by pathological changes associated with ARDS. In aged mice, a greater number of differentially expressed genes were observed than in young mice, whose responses were significantly delayed. Differences between lethal and nonlethal virus phenotypes in aged mice could be attributed to differences in host response kinetics rather than virus kinetics. SARS-CoV infection induced a range of interferon, cytokine, and pulmonary wound-healing genes, as well as several genes associated with the onset of ARDS. Mice that died also showed unique transcriptional profiles of immune response, apoptosis, cell cycle control, and stress. Cytokines associated with ARDS were significantly upregulated in animals experiencing lung pathology and lethal disease, while the same animals experienced downregulation of the ACE2 receptor. These data suggest that the magnitude and kinetics of a disproportionately strong host innate immune response contributed to severe respiratory stress and lethality. Although the molecular mechanisms governing ARDS pathophysiology remain unknown in aged animals, these studies reveal a strategy for dissecting the genetic pathways by which SARS-CoV infection induces changes in the host response, leading to death.

Sign in / Sign up

Export Citation Format

Share Document